A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Status:
Completed
Trial end date:
2017-10-16
Target enrollment:
Participant gender:
Summary
Purpose: This study is a single-arm, open-label phase II clinical trial testing the
hypothesis that daily everolimus plus weekly vinorelbine and trastuzumab will be effective,
safe, and tolerable among patients with human epidermal growth factor receptor 2
(HER2)-positive breast cancer brain metastases. Once enrolled, patients will receive
everolimus PO daily in combination with weekly intravenous (IV) vinorelbine and trastuzumab.
Cycles will be repeated every 3 weeks (21 days). At the time of progression, patients will
come off study.
Participants: Up to 35 adults over 21 with HER-2 positive breast cancer that has metastasized
to the brain.